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Abstract
Background:  This study was designed to mainly evaluate the activity and safety of olanzapine compared with 5-
hydroxytryptamine3(5-HT3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting(CINV) in
patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC). The second goal was to evaluate the impact
of olanzapine on quality of life (QoL) of cancer patients during the period of chemotherapy.
Methods: 229 patients receiving highly or moderately emetogenic chemotherapy were randomly assigned to the test group
[olanzapine(O) 10 mg p.o. plus azasetron (A) 10 mg i.v. and dexamethasone (D) 10 mg i.v. on day 1; O 10 mg once a day on
days 2-5] or the control group (A 10 mg i.v. and D 10 mg i.v. on day 1; D 10 mg i.v. once a day on days 2-5). All the patients
filled the observation table of CINV once a day on days 1-5, patients were instructed to fill the EORTC QLQ-C30 QoL
observation table on day 0 and day 6. The primary endpoint was the complete response (CR) (without nausea and vomiting, no
rescue therapy) for the acute period (24 h postchemotherapy), delayed period (days 2-5 poschemotherapy), the whole period
(days 1-5 postchemotherapy). The second endpoint was QoL during chemotherapy administration, drug safety and toxicity.
Results: 229 patients were evaluable for efficacy. Compared with control group, complete response for acute nausea and
vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly
emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p
< 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively
improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole
period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus
28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in
patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43%
(89.23% versus 75.80%, p < 0.05). 214 of 299 patients were evaluable for QoL. Comparing test group with control group in QoL
evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and
vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01). Both treatments were well tolerated.
Conclusion: Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or
moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the
cancer patients during chemotherapy administration. Olanzapine is a safe and efficient drug for prevention of CINV.
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Background
Chemotherapy-induced nausea and vomiting is a signifi-
cant side effect of cancer therapy for many years[1]. CR for
acute period and delayed period in the patients receiving
highly and moderately emetogenic chemotherapy with
the use of 5-HT3 receptor antagonists plus dexamethasone
is respectively 68%-90% and 47%-56%. Despite the use of
5-HT3 receptor antagonists plus dexamethasone has sig-
nificantly improved the control of the acute CINV, the
complete response for the delayed nausea and vomiting
has not significantly improved comparing with the sole
use of dexamethasone[2]. Recent studies have demon-
strated additional improvement in the control of acute
and delayed CINV with the use of two new agents, aprepi-
tant, the first agent available in the new drug class of
neruokinin-1 receptor antagonists, and palonosetron, a
second-generation 5-HT3  receptor antagonist [3-5].
Because without of the application of the two new drugs
in China, we still have many chance for improvement
with the addition or substitution of new agents in current
antiemetic regimens.
Olanzapine, an atypical antipsychotic drug, blocks multi-
ple neurotransmitters: serotonin, at 5H2a, 5H2c, 5H3,
and 5HT6 receptors, dopamine at D1, D2, D3 and D4
brain receptor, catecholamines at alpha 1 adrenergic
receptors, acetylcholine at muscarinic receptors, and his-
tamine at H1 receptors. Just for its action at multiple
receptors sites, particularly at the D2 and 5H3 receptors,
which appear to be involved in nausea and vomiting, sug-
gest that it has potential antiemetic properties.
At first some case reports shew that olanzapine was effec-
tive in reduction nausea in advanced cancer patients with
opioid-induced nausea [6,7]. Another study reported that
olanzapine may decrease delayed emesis in 28 cancer
patients treated with highly or moderately emetogenic
chemotherapy [8]. Then a phase I study made sure the
maximum tolerated dose of olanzapine which is 5 mg per
day for the 2 days prior to chemotherapy and 10 mg per
day for 7 days postchemotherapy[9]. It had safe and effec-
tive use for the prevention of delayed emesis in cancer
patients receiving moderately to highly emetogenic chem-
otherapy such as cyclophosphamide, doxorubicin, cispla-
tin, and/or irinotecan. In a II stage trial of olanzapine[10]
in combination with granisetron and dexamethasone for
prevention of CINV, the combination therapy proved to
be highly effective in controlling acute and delayed CINV
in patients receiving highly and moderately emetogenic
chemotherapy. CR for acute period, delayed period in ten
patients receiving highly emetogenic chemotherapy is
respectively 100% and 80%. Results for moderately eme-
togenic chemotherapy were similar. In order to reduce the
side effect of dexamethasone, Navari designed a II stage
trial to determine the control of acute and delayed CINV
in patients receiving moderately and highly emetogenic
chemotherapy with the combined use of palonosetron,
olanzapine and dexamehthasone which was given on day
1 only. For the first cycle of chemotherapy, the complete
response (no emesis, no rescue) for the acute, delayed and
overall period was respectively 100%, 75%, and 75% in 8
patients receiving HEC and 97%, 75%, and 72% in 32
patients receiving MEC. Patients with no nausea for the
acute, delayed, and overall period was respectively 100%,
50% and 50% in 8 patients receiving HEC and was
100%,78%, and 78% in 32 patients receiving MEC. The
result shew that olanzapine combined with a single dose
of dexamethasone and a single dose of palonosetron was
very effective in controlling acute and delayed CINV in
patients receiving both HEC and MEC.
Based on these data, olanzapine appear to be a safe and
effective agent for prevention acute and delayed CINV in
spite of a few of patients. At present the antiemetic regi-
men is the combination of 5-HT3 receptor antagonist, dex-
amethasone and/or metoclopramide, diazepam in China.
In an attempt to improve the complete remission of the
acute and delayed emesis, we preformed a study used with
the combination of olanzapine, azasetron and dexameth-
asone for prevention acute and delayed nausea and vom-
iting induced by highly or moderately emetogenic
chemotherapy.
Methods
Patient selection
The adult patients with a pathological diagnosis of malig-
nant disease or previously treated by chemotherapy were
enrolled onto the study and received either moderately
emetogenic (oxaliplatin, carboplatin, epirubicin, adri-
amycin) or highly emetogenic (cisplatin, dacarbazine)
chemotherapy. Patients were required to have adequate
bone marrow (absolute neutrophil count ≥ 1,500/ul, HB
≥ 10 g/L, platelet count ≥ 80,000/ul), renal (serum creati-
nine ≤ 1.5 mg/dl) and liver (serum bilirubin ≤ 1.5 mg/dl)
functions, normal cardiac function, ECOG performance
status ≤ 2, no nausea in the 24 h prior to beginning olan-
zapine or chemotherapy, no severe cognitive compro-
mise, no known history of CNS disease (e.g., uncontrolled
brain metastases, seizure disorder), no antipsychotic dis-
ease, no concurrent abdominal radiotherapy, no know
hypersensitivity to olanzapine, no history of uncontrolled
diabetes mellitus, no concurrent medical disease. All
patients gave written informed consent to participate in
the trial.
Study design and antiemetic treatment
All eligible patients were randomized into test group and
control group according to the random digits table. On
the day of chemotherapy, day 1, the test group patients
received the antiemetic regimen consist of olanzapine 10
mg p.o., azasetron 10 mg, i.v. and dexamethasone 10 mg
i.v., the control group patients received a standard pre-Journal of Experimental & Clinical Cancer Research 2009, 28:131 http://www.jeccr.com/content/28/1/131
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treatment antiemetic regimen consist of azasetron 10 mg,
i.v. and dexamethasone 10 mg, i.v. Day 2-5, the test group
patients received olanzapine 10 mg p.o., the control
group patients received dexamethasone 10 mg, i.v..
Patients were permitted to take other antiemetic therapy
for nausea and/or emesis based on clinical circumstances.
Study endpoints
The primary endpoint was CR, the second endpoint was
QoL, drug safety and toxicity. CINV was graded by CTCAE
V 3.0, QoL was evaluated according to EORTC QLQ-C30.
Assessment procedures
All of the enrolled patients whose data such as age, sex,
height, weight should be recorded underwent a complete
physical examination, laboratory assessment (i.e. blood
analysis, liver function, renal function, blood glucose,
blood lipids) before chemotherapy. At days 1-5 postch-
emotherapy patients used the observation table of CINV
to record the response of the patients (mainly recorded
the degree of CINV, as well as whether to take the reme-
dial treatment to relieve nausea and vomiting), at same
time patients were instructed to fill the EORTC QLQ-C30
QoL observation table on day 0 and day 6.
Statistical analyses
Statistical analyses were carried out using SPSS14.0. The
percentage of patients with complete response for acute
period, delayed period and the overall period (0-120 h
postchemotherapy) was calculated separately in test
group and control group, as well as every level of nausea
and vomiting. The X2 test was utilized to analyze complete
response. The Wilcoxon-signed rank test was used to com-
pare QoL data before and after chemotherapy. Student's t-
test was used to compare parametric QoL data postchem-
otherapy between groups. The Mann-Whitney U test was
performed to compare non-parametric QoL data postch-
emotherapy between groups. P-value of < 0.05 was con-
sidered as statistically significant.
Results
Patients characteristics
From January 2008 to August 2008,229 patients were ran-
domly enrolled onto the study. All patients were evalua-
ble for efficacy and toxicity. Groups were comparable
regarding age, sex and drug which distribution were bal-
anced (p > 0.05) (Table 1). All patients received chemo-
therapy. There were 108 patients in test group and 106
patients in control group who took part in filling QoL
assessment.
Primary efficacy analysis
Both of test group and control group had showed better
efficacy on controlling CINV. Comparison of drug efficacy
was shown in Table 2. Compared with control group,
complete response for acute period in test group with
highly or moderately emetogenic chemotherapy had no
difference (p > 0.05), complete response for delayed nau-
sea and vomiting in patients with highly emetogenic
chemotherapy respectively improved 39.21%(69.64%
versus 30.43%, p < 0.05), 22.05% (78.57% versus
56.52%, p < 0.05), complete response for delayed nausea
and vomiting in patients with moderately emetogenic
chemotherapy respectively improved 25.01%(83.07%
versus 58.06%, p < 0.05), 13.43% (89.23%
versus75.80%, p < 0.05), complete response for the whole
period of nausea and vomiting in patients with highly
emetogenic chemotherapy respectively improved 41.38%
(69.64% versus 28.26%, p < 0.05), 22.05% (78.57% ver-
sus 56.52%, p < 0.05), complete response for the whole
period of nausea and vomiting in patients with moder-
ately emetogenic chemotherapy respectively improved
26.62% (83.07% versus 56.45%, p < 0.05), 13.43%
(89.23% versus 75.80%, p < 0.05). Age was significantly
correlated with acute, delayed and the whole period nau-
sea in the level of 0.01.
The results of further classification for CINV were shown
in Table 3. Test group and control group had achieved bet-
ter efficacy without of acute nausea and vomiting prior to
level 3 and delayed acute nausea and vomiting prior to
level 4. Complete response for level 1 acute nausea, level
3 delayed nausea and vomiting were 100% in test group,
but there were no statistically difference compared with
control group (p > 0.05). The efficacy for level 2 acute or
delayed nausea and vomiting in test group were superior
to control group (p < 0.05).
Secondary efficacy parameters
There were 214 patients whose QoL data could be evalu-
ated. The QLQ-C30 responses were scored and analyzed
according to algorithms in a scoring manual supplied by
the EORTC Study Group on Quality of life. An increased
score for a functional domain and global QoL scale repre-
sents an improvement of functioning, an decreased score
for a symptom scale represents an improvement of symp-
tomatic problem. After chemotherapy an improvement in
global health status, emotional functioning, cognitive
functioning, pain, dyspnoea, insomnia, appetite loss were
seen in test group, but no difference in cognitive function-
ing, dyspnoea and appetite loss were seen (p > 0.05). After
chemotherapy an improvement in pain and dyspnoea
were seen in the control group, but no difference in pain
was seen (p > 0.05). Comparing test group and control
group in QoL evolution, significant differences were seen
in global health status, emotional functioning, social
functioning, fatigue, nausea and vomiting, insomnia and
appetite loss evolution in favour of test group (p < 0.01).
All the enrolled patients had completed the study. 73% of
patients in test group had sleepiness during chemother-
apy, but after chemotherapy weight, blood lipoid andJournal of Experimental & Clinical Cancer Research 2009, 28:131 http://www.jeccr.com/content/28/1/131
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blood glucose did not change significantly. Fatigue, head-
ache, dry mouth, diarrhea were common adverse events in
two groups but did not result in level 3 or 4 toxicity, which
could be tolerated by two groups patients. Most patients
in control group had disturbed sleep during chemother-
apy which could be relieved by oral estazolam.
Discussion
Although 5-HT3 receptor antagonists have been particu-
larly effectively for the acute CINV [11-13], they have not
effective against the delayed CINV in patients receiving
highly or moderately emetogenic chemotherapy [14].
They have the same efficacy as dexamethation for preven-
tion of the delayed CINV [2], so this study compared olan-
zapine regimen with the standard therapy regimen to
evaluate their effect for CINV in patients receiving highly
or moderately emetogenic chemotherapy. In the present
study, the effect of two regimens were similar to the acute
nausea and vomiting, but the olanzapine regimen pro-
tected more than two-thirds of patients from emesis after
Table 1: characteristics of patients in two groups
Test group Control group
Number of patients 121 108
Age range (mean standard deviation)
male 40-73(54 ± 9.23) 41-74(54.5 ± 10.33)
female 27-68(48.25 ± 12.70) 18-67(49.58 ± 12.12)
Gender
Male 72 (59.50%) 65 (60.20%)
Female 49 (40.50%) 43 (39.80%)
Drug
Cisplain(75 mg/m2) 56 (46.30%) 44 (40.70%)
Oxaliplatin(85 mg/m2) 27 (22.30%) 26 (24.10%)
Epirubicin(90 mg/m2) 19 (15.7%) 22 (20.4%)
Carboplatin(AUC 5) 9 (7.40%) 4 (3.7%)
Adriamycin(50 mg/m2) 10 (8.3%) 10 (9.3%)
Dacarbazine(200 mg/m2)0 2 ( 1 . 9 % )
Cancer type
Lung 39 15
Stomach 9 12
Breast 23 31
Ovarian 10 2
Lymphoma 12 10
Oesophageal 5 6
Colorectal 16 14
Oropharyngeal 3 0
Teratoma 4 0
Gingival 0 3
Thymus 0 4
Cervical 0 4
Laryngeal 0 2
Malignant melanoma 0 3
Glioblastoma 0 2
Table 2: Complete response of CINV
Complete response (%)
AN AV DN DV NC VC
HMHMHMHMHMHM
TG 94.64 98.46 91.07 96.92 69.64 83.07 78.57 89.23 69.64 83.07 78.57 89.23
CG 86.96 93.54 89.13 96.77 30.43 58.06 56.52 75.80 28.26 56.45 56.52 75.80
P value > 0.05 > 0.05 < 0.05 < 0.05 < 0.05 < 0.05
AN: acute nausea, AV: acute vomiting, DN: delayed nausea, DV: delayed vomiting, NC: nausea of whole period of chemotherapy, VC: vomiting of 
whole period of chemotherapy, TG: test group, CG: control group, H: highly emetogenic chemotherapy, M: moderately emetogenic chemotherapyJournal of Experimental & Clinical Cancer Research 2009, 28:131 http://www.jeccr.com/content/28/1/131
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they received highly or moderately emetogenic chemo-
therapy and enabled them to avoid the use of rescue ther-
apy during 2-4 days after chemotherapy, whereas
treatment of control group with the currently available
standard therapy protected approximately half of patients.
The superiority of olanzapine for control of delayed nau-
sea and vomiting caused by highly emetogenic chemo-
therapy is more than its roles on delayed nausea and
vomiting caused by moderately emetogenic chemother-
apy. In the assessments of complete response over the
period after chemotherapy, the olanzapine regimen pro-
vided a substantial improvement of 41 and 26 percent
points and 22 and 13 percent points over standard ther-
apy in the prevention of nausea and vomiting after highly
and moderately emetogenic chemotherapy, this repre-
sented a clearly meaningful benefit.
Recent studies demonstrated that the acute emesis is
mainly associated with serotonin, so 5-HT3  receptor
antagonists have a dramatically effect on the acute emesis
in many trials, but delayed emesis seems to differ in its
pathogenic mechanism from acute emesis because drugs
that are so effective in preventing the acute emesis are less
effective in the delayed period such as 5-HT3 receptor
antagonist. Olanzapine blocks multiple neurotransmit-
ters which are known mediators of CINV. Olanzapine
appears to have activity in control acute and delayed nau-
sea and vomiting.
According to CTCAE V3.0, level 1 of nausea means loss of
appetite without alteration in eating habits, level 2 means
oral intake decreased without significant weight loss,
dehydration or malnutrition; IV fluids, indicated < 24 hrs,
level 3 means inadequate oral caloric and/or fluid intake,
IV fluids, tube feedings, or TPN indicated > = 24 hrs. Level
1 of vomiting means 1 episode in 24 hrs, level 2 means 2-
5 episodes in 24 hrs; IV fluids indicated < 24 hrs, level 3
means > = 6 episodes in 24 hrs; IV fluids, or TPN indicated
> = 24 hrs. This study of further classification for nausea
and vomiting showed that olanzapine regimen had statis-
tical difference in controlling level 2 acute or delayed nau-
sea and vomiting from standard therapy regimen for
CINV opposite to controlling level 1 nausea and vomit-
ing. This meant that olanzapine could relieve the degree
of acute or delayed nausea and vomiting and improve the
efficacy of its antiemetic role.
Dexamethasone is effective as monotherapy and in com-
bination with 5-HT3 receptor antagonist to prevent acute
and delayed nausea and vomiting in patients receiving a
chemotherapeutic regimens used for treatment of differ-
ent cancers. However, one must be aware of potential
toxic effects of dexamethasone. In a recent survey, moder-
ate-to-severe side-effects noted for patients receiving dex-
amethasone for prophylaxis against delayed CINV
included insomnia (45%), gastrointestinal symptoms
(27%), agitation (25%), increased appetite (18%), weight
gain (17%), rash (15%), depression on cessation of treat-
ment (7%), hiccups (7%) and oral candidiasis (3%)[15].
In order to try one' best to relieve the side-effects of dex-
amethasone, olanzapine was separately used to prevent
the delayed nausea and vomiting comparing with dexam-
ethasone for delayed nausea and vomiting in patients
receiving highly or moderately chemotherapy in this
study. Olanzapine in combination with 5-HT3 receptor
antagonist and dexamethasone was shown to be superior
to 5-HT3 receptor antagonist and dexamethasone in con-
trolling the acute and delayed CINV in patients receiving
Table 3: Complete response of CINV in different grade
Complete response (%)
AN AV DN DV
L1 L2 L1 L2 L1 L2 L3 L1 L2 L3
TG 96.70 97.52 97.52 99.17 90.08 94.21 100 93.39 96.70 100
CG 100 87.04 97.22 91.66 82.40 62.96 99.07 89.81 76.85 99.07
P value > 0.05 < 0.05 > 0.05 < 0.05 > 0.05 < 0.05 > 0.05 > 0.05 < 0.05 > 0.05
Definition of nausea according to CTCAE V 3.0
L1: Loss of appetite without alteration in eating habits
L2: Oral intake decreased without significant weight loss, dehydration or malnutrition; IV fluids, indicated < 24 hrs.
L3: inadequate oral caloric and/or fluid intake, IV fluids, tube feedings, or TPN indicated ≥ 24 hrs
L4: Life-threatening consequences
L5: Death
Definition of nausea according to CTCAE V 3.0
L1: 1 episode in 24 hrs
L2: 2-5 episodes in 24 hrs; IV fluids indicated < 24 hrs
L3: > = 6 episodes in 24 hrs; IV fluids, or TPN indicated > = 24 hrs
L4: Life-threatening consequences
L5: DeathJournal of Experimental & Clinical Cancer Research 2009, 28:131 http://www.jeccr.com/content/28/1/131
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highly or moderately emetogenic chemotherapy, specifi-
cally for the delayed nausea and vomiting. The severe
toxic effects of olanzapine was not seen in this clinical
study. The most frequent side-effect was sleepiness which
could effectively relieve insomnia and agitation caused by
dexamethasone.
The diagnosis of cancer is a life-altering experience for
anyone. Some cancer patients could have inevitable emo-
tions that can interfere with medical care, family, diet,
sleep, exercise. The more common diagnosed psychiatric
conditions are depression, anxiety, adjustment disorders,
delirium. Often, patients have mixed states or combina-
tions of symptoms, such as depression and anxiety. Olan-
zapine is an atypical antipsychotic drug, some studies
have demonstrated the antidepressant efficacy of olanza-
pine [16,17]. In this study, whether the use of olanzapine
for five days could result in the improvement of QoL
because of its antipsychotic effects, which need to further
study for no relevant studies to be reported. But we
observed olanzapine not only elevated the complete
response for CINV, specially for the delayed nausea and
vomiting but also improved the emotion, sleep, appetite
of the cancer patients compared with the standard therapy
regimen of antiemesis. Improvement of the cancer
patients QoL during chemotherapy can make the patients
more confidence for treatment which can make the
patients complete the whole treatment. This will result in
the improvement of the clinical efficacy.
Conclusion
In summary, this study demonstrated that olanzapine has
obtained the better efficacy on being safely used for pre-
venting the CINV. Olanzapine can improve the complete
response of delayed nausea and vomiting in patients
receiving the highly or moderately emetogenic chemo-
therapy comparing with the standard therapy of antieme-
sis, as well as improve the QoL of the cancer patients
during chemotherapy. Olanzapine is a safe and efficient
drug for prevention of CINV. Further study should be
done to compare the efficacy of olanzapine with aprepi-
tant or palonosetron on prevention of CINV through large
sample study.
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